Search results for " liver transplant"

showing 10 items of 77 documents

Brain core temperature of patients before and after orthotopic liver transplantation assessed by diffusion weighted imaging thermometry

2018

Aims and objectives Methods and materials Results Conclusion Personal information References

Cerebrospinal fluidgenetic structuresCirrhosisCNSDWI Thermometry liver transplantationMR-Diffusion/PerfusionExperimental investigations
researchProduct

Der Einfluss des RANTES −403 Genpolymorphismus auf den Langzeitverlauf nach orthotoper Lebertransplantation

2005

Introduction: By the recruitment of leukocytes chemokines are able to mediate a protective as well as a harming influence on rejections after human orthotopic liver transplantation. There is a base exchange (G/A) known at position-403 in the RANTES promoter region which leads to an increased RANTES expression. Due to the crucial influence of a raised hepatic RANTES synthesis on the course after liver transplantation we investigated the effect of the RANTES −403 polymorphism on organ survival and rejection frequency. Materials and methods: Genomic DNA has been extracted from EDTA-blood of liver transplanted patients. The RANTES −403 polymorphism has been analysed by hybridisation with FRET (…

ChemokineBase exchangeOrthotopic liver transplantationbiologybusiness.industrymedicine.medical_treatmentOrgan Survivalbiology.proteinMedicinePromoterLiver transplantationbusinessMolecular biology
researchProduct

Brain Core Temperature of Patients Before and After Orthotopic Liver Transplantation Assessed by DWI-Thermometry

2019

Purpose The brain produces heat as a result of cerebral metabolism, and the heat is removed mainly through circulation of the intracranial blood vessels and cerebrospinal fluid (CSF). The aim of this study was to assess the brain core temperature of adult patients with end stage liver disease before and after orthotopic liver transplantation (OLT) using a noninvasive temperature measurement technique based on the diffusion coefficient of the cerebrospinal fluid. Materials and Methods This retrospective study used the data collected from January, 2014 to January, 2017. The study group comprised 19 patients (16 men, 3 women, mean age 57.9 ± 7.4 years) with a MELD score 23.7 who underwent magn…

DWI Thermometry Brain Orthotopic Liver Transplantation
researchProduct

Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: A multicenter European experience

2019

During the last decades, several risk factors for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) have been investigated. However, the impact of two important drivers of oncogenesis, namely the immunosuppression and the treatment of acute cellular rejection (ACR) have been marginally addressed. This study aimed at investigating the impact of ACR treatment on the incidence of tumor recurrence in a large European HCC-LT population. Seven hundred and eighty-one adult patients transplanted between February 1, 1985 and June 30, 2016 were retrospectively analyzed. After propensity score match, 116 patients treated for ACR using steroid boluses were compared with …

Graft RejectionMaleTime Factorsmedicine.medical_treatmentLiver transplantationGastroenterologyAcute rejection; Liver biopsy; Liver transplantation; Recurrence; Steroid0302 clinical medicineRisk FactorsRecurrenceProspective cohort studyeducation.field_of_studymedicine.diagnostic_testIncidenceIncidence (epidemiology)Liver NeoplasmsGastroenterologyImmunosuppressionMiddle AgedLiver biopsyAllograftsEuropeTreatment Outcome030220 oncology & carcinogenesisLiver biopsyHepatocellular carcinomaAcute rejectionFemaleSteroids030211 gastroenterology & hepatologyImmunosuppressive Agentsmedicine.medical_specialtyCarcinoma HepatocellularPopulationRisk Assessment03 medical and health sciencesInternal medicinemedicineHumanseducationSteroidRetrospective StudiesLiver transplantationHepatologybusiness.industrymedicine.diseaseLiver TransplantationTransplantationNeoplasm Recurrence LocalbusinessHepatobiliary & Pancreatic Diseases International
researchProduct

Metabolomics discloses donor liver biomarkers associated with early allograft dysfunction

2014

Background & Aims Early allograft dysfunction (EAD) dramatically influences graft and patient outcome after orthotopic liver transplantation and its incidence is strongly determined by donor liver quality. Nevertheless, objective biomarkers, which can assess graft quality and anticipate organ function, are still lacking. This study aims to investigate whether there is a preoperative donor liver metabolomic biosignature associated with EAD. Methods A comprehensive metabolomic profiling of 124 donor liver biopsies collected before transplantation was performed by mass spectrometry coupled to liquid chromatography. Donor liver grafts were classified into two groups: showing EAD and immediate g…

Graft RejectionMalemedicine.medical_specialtyOrthotopic liver transplantationmedicine.drug_classBiopsyHistidine MetabolismGastroenterologyBile Acids and SaltsModel for End-Stage Liver DiseaseMetabolomicsPredictive Value of TestsRisk FactorsInternal medicineLipidomicsmedicineHumansMetabolomicsHistidinePhospholipidsHepatologyBile acidbusiness.industryMiddle AgedAllograftsTissue DonorsLiver TransplantationSphingomyelinsTransplantationLiverBiochemistryFemaleLysophospholipidsbusinessLiving donor liver transplantationBiomarkersJournal of Hepatology
researchProduct

Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Regist…

2019

BACKGROUND: We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. METHODS: Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T.…

Graft RejectionMalemedicine.medical_specialtyTime FactorsDrug Compoundingmedicine.medical_treatmentCalcineurin InhibitorsMedizinMEDLINEchemical and pharmacologic phenomenaLiver Transplant030230 surgeryLiver transplantationRisk AssessmentTacrolimusall contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA)03 medical and health sciences0302 clinical medicineRisk FactorsProlonged releaseInternal medicinemedicineHumansAged; Calcineurin Inhibitors; Delayed-Action Preparations; Drug Compounding; Europe; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Male; Middle Aged; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Tacrolimus; Time Factors; Treatment Outcome; Liver TransplantationRegistriesAgedRetrospective StudiesTransplantationbusiness.industryGraft SurvivalImmunosuppressionRetrospective cohort studyMiddle AgedTacrolimusSettore MED/18Liver Transplantation3. Good healthEuropeTreatment Outcomesurgical procedures operativeDelayed-Action PreparationsFemale030211 gastroenterology & hepatologyTransplant patientbusinessRisk assessmentImmunosuppressive AgentsTransplantation
researchProduct

Prophylaxis and treatment of hepatitis B in immunocompromised patients.

2007

The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunos…

HBsAgmedicine.medical_specialtyHepatitis C virusmedicine.medical_treatmentLiver transplantationTransplantmedicine.disease_causeGastroenterologyAntiviral AgentsImmunocompromised HostAnimals; Antiviral Agents; Carrier State; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Humans; Immunocompromised Host; Liver Transplantation; Tissue Donors; TransplantationAntivirals; HBV; Immunosuppression; Transplants;Internal medicineHBVMedicineAnimalsHumansAntiviralHepatitis B virusTransplantationHepatitis B Surface AntigensHepatologybusiness.industryGastroenterologyvirus diseasesHepatitis Bmedicine.diseaseHepatitis BHepatitis B Core Antigensdigestive system diseasesTissue DonorsLiver TransplantationTransplantationHBeAgImmunologyCarrier StateHepatitis D virusbusinessImmunosuppression
researchProduct

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

2021

[Background & Aims] The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Hepatocellular carcinomaLCmedicine.medical_treatment:diagnóstico::toma de decisiones clínicas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]NursesRC799-869Liver transplantationCholangiocarcinomaClinical trialsENS-CCAInterquartile rangeDecisió Presa dePandemic:Other subheadings::/diagnosis [Other subheadings]:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]CERO-19Pandèmia de COVID-19 2020-Immunology and AllergyiCCA intrahepatic cholangiocarcinomaCOVID-19 coronavirus disease 2019Liver Cancer Outcome in the COVID-19-pandemic ProjectSettore MED/12 - Gastroenterologiaddc:617IQRGastroenterologyBCLC Barcelona Clinic Liver Cancer:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas [ENFERMEDADES]Diseases of the digestive system. GastroenterologyManagementClinical PracticeClinical trialEuropean Network for the Study of Cholangiocarcinoma:Diagnosis::Clinical Decision-Making [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Fetge - Malalties - DiagnòsticInterquartile rangeLiver cancerLiver cancerPROGRESSION-FREE SURVIVALLiver Cancermedicine.medical_specialtyCoronavirus disease 2019 (COVID-19):Otros calificadores::/diagnóstico [Otros calificadores]610 Medicine & health:Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [DISEASES]LT liver transplantationArticleBarcelona Clinic Liver CancerInternal MedicinemedicineENS-CCA European Network for the Study of CholangiocarcinomaHepatologybusiness.industryCERO-19 Liver Cancer Outcome in the COVID-19-pandemic ProjectCOVID-19IQR Interquartile rangemedicine.diseaseBCLCClinical trialEmergency medicineObservational study610 Medizin und GesundheitbusinessHCC hepatocellular carcinomaLC liver cancerSARS-CoV-2 severe acute respiratory syndrome coronavirus-2
researchProduct

Comparison of two different techniques of reperfusion in adult orthotopic liver transplantation

2006

: The aim of this study was to determine the impact of two reperfusion techniques on the peri-operative hemodynamic changes and early post-operative graft function of adult patients undergoing orthotopic liver transplantation. Material and methods: From June 2003 to May 2004, 50 consecutive liver transplants were performed and divided into two groups: group A, 25 patients, portal vein flush with 500 cm3 of Ringer's lactate without vena caval venting. Group B, 25 patients, vena caval venting with no portal vein flush. Donor and recipient characteristics were similar in both groups. Sixty-four different parameters were analyzed, and Pearson's χ2 test and t-test were used for statistical analy…

InferiorAdultMalemedicine.medical_specialtyOrthotopic liver transplantation; Post-reperfusion syndrome; Reperfusion technique; Adolescent; Adult; Aged; Aged 80 and over; Child; Female; Humans; Liver Transplantation; Male; Middle Aged; Portal Vein; Reperfusion; Tissue Donors; Vena Cava Inferior; TransplantationVena CavaAdolescentOrthotopic liver transplantationmedicine.medical_treatmentPortal veinHemodynamicsPost-reperfusion syndromeVena Cava InferiorLiver transplantationVena caval80 and overmedicineHumansStatistical analysisChildAgedAged 80 and overReperfusion techniqueTransplantationAdult patientsPortal Veinbusiness.industrySignificant differenceMiddle AgedSettore ING-IND/35 - Ingegneria Economico-GestionaleTissue DonorsLiver TransplantationSurgerySettore MED/18 - Chirurgia GeneraleReperfusioncardiovascular systemFemaleOrthotopic liver transplantationbusinessClinical Transplantation
researchProduct

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

2010

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Liver CirrhosisANTIVIRAL TREATMENTHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusANTIVIRAL THERAPY; PEGYLATED INTERFERON-ALPHA-2B; LIVER-TRANSPLANTATION; PEGINTERFERON ALPHA-2A; HIV-INFECTED PATIENTS; VIRUS-COINFECTED PATIENTS; RAPID VIROLOGICAL RESPONSEAntiviral therapymedicine.disease_causeGastroenterologyPolyethylene GlycolsHBVguidelinesAcute hepatitisChronic hepatitisSettore MED/12 - Gastroenterologialiver transplantationGastroenterologyAntiviral therapyHepatitis CVIRUS-COINFECTED PATIENTSLIVER-TRANSPLANTATIONHepatitis CRecombinant Proteinsacute hepatitis; antiviral therapy; chronic hepatitis; cirrhosis; elderly patients; hbv; hcv; hdv; hiv; liver transplantationCLINICAL PRACTICE GUIDELINESCirrhosisHCVDrug Therapy CombinationAntiviral therapy Acute hepatitis Chronic hepatitisCirrhosis Elderly patients HBV HCV HDV HIV Liver transplantationElderly patientAcute hepatitiAcute hepatitismedicine.medical_specialtyGenotypePEGINTERFERON ALPHA-2AAlpha interferonHIV-INFECTED PATIENTSInterferon alpha-2CHRONIC HEPATITIS CAntiviral AgentsHepatitis B ChronicChronic hepatitisInternal medicineHDVDrug Resistance ViralRibavirinmedicineHumansPEGYLATED INTERFERON-ALPHA-2BCirrhosiHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAInterferon-alphaHIVHepatitis C Chronicmedicine.diseaseElderly patientsFamily medicineExpert opinionAntiviral therapy; Acute hepatitis; Chronic hepatitis; Cirrhosis; Elderly patients; HBV; HCV; HDV; HIV; liver transplantationChronic hepatitiRAPID VIROLOGICAL RESPONSEbusinessCHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; CLINICAL PRACTICE GUIDELINES
researchProduct